ShareValue scores for DRMA: Valuation 52, Quality 49, Growth 45, Health 55.

Dermata Therapeutics Inc logo

DRMA
NASDAQ

Dermata Therapeutics Inc

$1.11(-5.13%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

6% to 16%
Valuation
52
Fair Value
Price vs Value
Quality
49
Moderate
Business Strength
Growth
45
Moderate
Revenue & Earnings
Health
55
Moderate
Financial Stability
Momentum
45
Neutral
Price Trend

Company Details

About

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026